Attovia Therapeutics, Inc. ATTO
15.11 USD -0.16 (-1.05%)
Nov 4, 2026, 2:30 PM EST
14.57 Day range 15.78
12.94 52-week range 28.00
- YTD
- -31.00%
- 1 year
- -31.00%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 42.20 +179.3% upside
Now 15.11
- Target (low)
- 30.00
- Target (mean)
- 42.20
- Target (high)
- 52.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.50 | -0.50 – -0.50 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Next quarter | -0.52 | -0.52 – -0.52 | 0.00 | 0.0% | 0 | 0.0% | 1 |
| Current year | -3.45 | -3.45 – -3.45 | 0.00 | 0.0% | 466.67K | 0.0% | 1 |
| Next year | -2.38 | -2.38 – -2.38 | -3.45 | +31.0% | 0 | -100.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 31, 2026 | Citigroup | Initiated | — | Buy |
| Aug 31, 2026 | LifeSci Capital | Initiated | — | Outperform |
| Aug 31, 2026 | Leerink Partners | Initiated | — | Outperform |
| Aug 31, 2026 | RBC Capital | Initiated | — | Outperform |
| Aug 31, 2026 | Morgan Stanley | Initiated | — | Overweight |